Illumina. has been granted a patent for a method to prepare a library of template polynucleotides with common sequences at both ends, facilitating solid-phase nucleic acid amplification. The method includes sequencing double-stranded polynucleotides with specific forked adapters, enhancing nucleic acid analysis. GlobalData’s report on Illumina gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Illumina, Microfluidics automation was a key innovation area identified from patents. Illumina's grant share as of July 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Method for preparing and sequencing nucleic acid libraries
The granted patent US12071711B2 outlines a method for sequencing a library of nucleic acids, specifically focusing on double-stranded polynucleotides that feature identical forked polynucleotide adapters at each end. These adapters consist of partially complementary strands, with at least one strand containing specific nucleotide sequences identified as SEQ ID NO:01, SEQ ID NO:02, or a complementary sequence to SEQ ID NO:04. The method includes sequencing the nucleic acid library, which may involve the successive addition of nucleotides to a free 3' hydroxyl group and determining the identity of each added nucleotide. The patent also allows for variations in the double-stranded polynucleotides, which can differ from one another, and includes provisions for amplifying the nucleic acid library prior to sequencing.
Further claims detail the amplification process, which can be conducted in solution or via solid-phase reactions on various supports such as glass or polystyrene. The method permits the use of a single primer, which may be surface-bound, and emphasizes the importance of mismatched regions in the adapters, where specific sequences at the ends of the strands are not complementary, allowing for single-stranded regions to remain after annealing. Additionally, the patent encompasses the sequencing of cDNA fragments and genomic DNA fragments, which can be sourced from either a single subject or multiple subjects, with a particular mention of human nucleic acids. This comprehensive approach aims to enhance the efficiency and specificity of nucleic acid sequencing techniques.
To know more about GlobalData’s detailed insights on Illumina, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
